10-K: Evolent Health Faces $579M Loss, Revenue Decline in 2025

Evolent Health reported a substantial net loss of $579.4 million and a 26.6% revenue decrease in 2025, driven by contractual changes and a $398.0 million goodwill impairment.

Summary

• Net loss attributable to common shareholders was $579.4 million in 2025, a significant increase from $93.5 million in 2024.
• Total revenue decreased by $678.5 million, or 26.6%, to $1,876.2 million for the year ended December 31, 2025, compared to $2,554.7 million in 2024.
• The revenue decrease was primarily due to $447.3 million from transitioning a customer from Performance Suite to Specialty Technology and Services Suite, and $267.4 million related to narrowing the scope of certain Performance Suite customers.
• A $398.0 million non-cash and non-tax-deductible goodwill impairment charge was recorded in 2025, resulting from a prolonged decline in the Class A common stock price.
• Operating loss significantly widened to $410.1 million in 2025 from $40.5 million in 2024.
• The Medical Expense Ratio (MER) excluding Evolent Care Partners improved to 89.0% in 2025 from 96.0% in 2024.
• The company completed the sale of Evolent Care Partners for a purchase price of $100.0 million, resulting in a gain on disposal of $14.9 million.
• Interest expense increased to $57.5 million in 2025 from $24.7 million in 2024, driven by new borrowings and the exchange of Series A Preferred Stock.
• Cash and cash equivalents stood at $151.9 million as of December 31, 2025, with total debt subject to interest at $934.0 million.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative filing due to the substantial net loss, significant revenue decline, and a large goodwill impairment charge, indicating severe financial underperformance and a challenging market environment. While there are some operational improvements in MER, the overall financial health has deteriorated significantly.

Positives

• Recorded a $14.9 million gain on the disposal of Evolent Care Partners.
• The Medical Expense Ratio (MER) excluding Evolent Care Partners improved to 89.0% in 2025 from 96.0% in 2024, indicating better efficiency in managing medical costs relative to revenue for that segment.
• Experienced $62.9 million of growth in other Performance Suite and Specialty Technology and Services contracts, partially offsetting larger revenue reductions.
• Successfully exchanged existing Series A Preferred Stock for a Second Lien Term Loan Facility, simplifying the capital structure.

Negatives

• Reported a significant net loss attributable to common shareholders of $579.4 million in 2025, compared to $93.5 million in 2024.
• Total revenue decreased by $678.5 million (26.6%) to $1,876.2 million in 2025.
• Recorded a $398.0 million non-cash goodwill impairment charge in 2025 due to a prolonged decline in Class A common stock price.
• Operating loss increased dramatically to $410.1 million in 2025 from $40.5 million in 2024.
• Interest expense increased to $57.5 million in 2025 from $24.7 million in 2024.
• Incurred a loss on option exercise of $52.5 million related to the purchase of an equity method investment.
• Selling, general, and administrative expenses increased by $40.8 million, or 15.5%, primarily due to higher personnel costs ($24.4 million, including $7.3 million in severance) and increased bad debt expense ($2.1 million).
• Medical claims costs in the Performance Suite grew significantly faster than historical norms in 2024 and 2025, negatively impacting financial results.
• Membership reductions at certain health plan clients resulted from Medicaid redeterminations and customers exiting Medicare Advantage operations.

Risks

• A significant portion of revenue is derived from a limited number of large partners, and the loss, termination, or renegotiation of these contracts could negatively impact results.
• Increasing risk-sharing arrangements with partners expose the company to unpredictable revenues and profitability, with potential for losses if exposure is not accurately predicted (e.g., rising oncology costs).
• Failure by customers to provide accurate and timely information could impact profitability and the ability to develop financial outlooks.
• Significant upfront costs in partner relationships may not be recovered if relationships do not grow or develop over time.
• Inability to attract new partners or successfully capture new opportunities with existing partners could harm financial projections.
• Failure to offer new and innovative products and services or keep pace with industry standards and technology (including AI) could lead to loss of partners.
• Dependency on key personnel and the ability to attract and retain employees, with intense competition and inflationary pressures increasing compensation costs.
• Risks related to completed and future acquisitions, investments, alliances, and joint ventures, including integration difficulties, unanticipated costs, and dilution.
• Inability to effectively manage growth and maintain an efficient cost structure, including offshore operations.
• The rapidly evolving value-based health care market and consolidation in the health care industry could adversely affect business and market share.
• Intense competition from technologically sophisticated entities, including those utilizing AI or machine learning, could limit market share and profitability.
• Offerings could be subject to audits by CMS and other governmental payers, and whistleblower claims under the False Claims Act, potentially leading to fines or reputational damage (e.g., current DOJ investigation).
• The uncertain and evolving healthcare regulatory and political framework, including new legislation like the One Big Beautiful Bill Act and increased scrutiny on AI in utilization management, could adversely affect financial condition.
• Data privacy and protection laws (HIPAA, HITECH Act, state laws) and cybersecurity risks, including potential breaches, data loss, and reputational harm, could lead to significant liabilities.
• Inability to obtain, maintain, and enforce intellectual property protection for technology and products, or allegations of infringement by third parties, could adversely affect business.
• Risks associated with the use of artificial intelligence and machine learning models, including incorrect design, lack of customer consent, and an evolving regulatory landscape.
• Reliance on third-party vendors to host and maintain technology platforms, and on Internet infrastructure, could lead to service disruptions.
• The company has experienced net losses in the past and may not achieve profitability in the future, potentially requiring additional financing.
• The company has recorded significant goodwill and intangible assets, and may incur additional impairment charges if their full value is not realized.
• Obligations to make material payments to pre-IPO investors under the Tax Receivables Agreement (TRA) for tax benefits, which could be substantial and potentially exceed realized tax benefits.
• Inability to obtain additional financing on favorable terms or at all, potentially resulting in a reduction in stockholder ownership.
• Conditional conversion features of the 2029 and 2031 Notes, if triggered, may adversely affect liquidity and financial condition.
• Exposure to interest rate risk under Credit Agreements could cause debt service obligations to increase significantly.
• Significant debt and other obligations could adversely affect financial health and flexibility.
• The stock price is expected to be volatile and may fluctuate or decline significantly.
• Provisions in corporate documents and Delaware law may deter third parties from acquiring the company.
• The company does not anticipate paying any cash dividends on its Class A common stock in the foreseeable future.
• The costs of compliance with sustainability or other environmental, social responsibility, or governance (ESG) laws, regulations, or policies could adversely affect the business.
• Inflationary pressures, rising consumer costs, and the current economic environment may negatively affect margins, profitability, and results of operations.
• The ability to utilize net operating loss carryforwards (NOLs) and certain other tax attributes may be limited under Internal Revenue Code Section 382.

Future Outlook

The company anticipates continued growth in the cost of treatment for cancer and cardiovascular patients, expecting this to be partially offset by contractual protections and clinical interventions. Broader policy shifts from the new administration, such as potential changes to Medicaid, could impact partner businesses. The company expects continued scrutiny and modifications to Medicare, Medicaid, and exchange programs, and is evaluating the impact of the One Big Beautiful Bill Act on its business and financial statements. The company also expects continued inflationary pressures on labor costs and other operating expenses.

Management Comments

• We believe adherence to evidence-based clinical pathways supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall.
• We believe Evolent can bring an integrated approach to a patient's condition across multiple specialties, using technology to recommend our evidence-based clinical pathways in a way that provides rapid feedback to the provider, seeks to remove barriers to care, and aligns financial incentives with the best evidence.
• We anticipate continued growth in the cost of treatment for cancer and cardiovascular patients over time, which we expect to be offset in part by contractual protections within our Performance Suite and the impact of our clinical interventions.
• We are unable to predict how these broader dynamics will impact our business and results of operations in the future, but they could continue to impact our financial condition and results of operations and such future impacts could be material.
• We do not believe these impacts [inflationary pressures] were material to our revenues or net loss for the year ended December 31, 2025, respectively. However, significant sustained inflation driven by the macroeconomic environment or other factors could negatively impact our margins, profitability and results of operations in future periods.

Industry Context

StockSavvy.ai notes that Evolent Health operates within a rapidly evolving and competitive healthcare technology landscape, characterized by a shift towards value-based care models and increasing adoption of AI and machine learning. The industry faces challenges from rising specialty care costs, regulatory changes (like the One Big Beautiful Bill Act and increased scrutiny on prior authorization), and consolidation among health plans and providers. Evolent's focus on integrated specialty care management for complex conditions like cancer and cardiovascular disease aligns with the industry's need for cost containment and quality improvement. However, the company's reliance on a few large partners and exposure to governmental funding changes reflect broader industry risks. Competitors are also incorporating advanced analytical tools and AI, intensifying the need for continuous innovation.

Comparison to Industry Standards

• The company noted that 'increasing oncology costs outpaced historical averages' and 'medical claims costs in our Performance Suite grew at a significantly faster rate than historical norms,' which, 'Based on commentary from other market participants, we believe these cost increases were industry-wide and not specific to Evolent.' This indicates that Evolent's experience with rising medical costs aligns with broader industry trends, rather than being an outlier.
• The filing does not provide specific comparable companies, projects, or results to global benchmarks for a detailed assessment against industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• Received a Civil Investigative Demand (CID) from the Department of Justice on August 12, 2025, pursuant to a False Claims Act investigation.
• The investigation concerns allegations that a former customer (not a customer since 2021) and/or certain other parties may have submitted, or caused the submission of, unsupported diagnosis codes in connection with Medicare Advantage beneficiaries, covering the period since January 1, 2016.
• The company is cooperating with the government but cannot predict the scope, duration, or outcome of this investigation, nor currently estimate the loss or range of possible losses.
• A shareholder derivative action filed in June 2021 alleging negligent oversight of a relationship with University Healthcare, Inc. d/b/a Passport Health Plan was dismissed without prejudice on January 5, 2023.
• A shareholder demand letter sent in April 2023 requesting an investigation and litigation for breach of fiduciary duty was refused by the Board on February 15, 2024.

Related Party Transactions

• An economic relationship with an entity whose President and Chief Executive Officer was a Board member until February 2024 accounted for the majority of related party revenue and cost of revenue in prior years.
• The company holds economic interests in several equity method investments and has entered into services agreements to provide management, operational, and support services to these entities, generating $12.5 million in revenue in 2025.

Stakeholder Impact

• Shareholders: Significant net loss and goodwill impairment could negatively impact stock price and investor confidence. No cash dividends are anticipated. Potential dilution from future equity raises is a risk.
• Employees: Increased severance costs and organizational changes indicate potential workforce adjustments. The company faces increased competition for qualified talent and inflationary pressures on wages.
• Customers (Partners): Contractual updates, scope narrowing, and membership reductions at health plan clients (due to Medicaid redeterminations and market exits) directly impacted revenue. There is a risk of further renegotiation or termination of contracts.
• Creditors: The company has significant debt ($934.0 million principal amount subject to interest) and is subject to restrictive covenants in its credit agreements, which could affect its ability to service debt and obtain future financing.

Next Steps

• Continue to evaluate the expected impact of the One Big Beautiful Bill Act on business and financial statements.
• Monitor for events or changes in circumstances that would indicate potential goodwill impairment triggers.
• Continue to invest significant resources in personnel and technology, including AI, to enhance existing products and services and introduce new ones.
• Selectively pursue strategic acquisitions, investments, and divestitures.
• The Proxy Statement for the Annual Meeting of Stockholders is scheduled to be filed by June 4, 2026.

Key Dates

Recommendation

The company reported a substantial net loss of $579.4 million, a 26.6% decline in revenue, and a $398.0 million goodwill impairment in 2025. These figures indicate significant financial deterioration and operational challenges. The ongoing Department of Justice investigation under the False Claims Act adds regulatory uncertainty and potential liabilities. While the company is making strategic adjustments and showing some efficiency gains in specific areas (like MER), the overall financial performance and the magnitude of the losses suggest a 'sell' recommendation for seasoned investors, as the risks and negative financial trends currently outweigh any potential long-term upside.

Keywords

Evolent Health, EVH, Healthcare Technology, Value-Based Care, Specialty Care Management, Oncology, Cardiology, Musculoskeletal, Radiology, Genetic Testing, Health Plans, Payer Solutions, Provider Networks, Clinical Pathways, AI in Healthcare, Machine Learning, Identifi Platform, CarePro Platform, SEC Filing, 10-K, Financial Results, Goodwill Impairment, Revenue Decline, Net Loss, Debt, Risk Management, Corporate Governance, Cybersecurity, HIPAA, HITECH Act, False Claims Act, Medicaid, Medicare Advantage, Inflation Reduction Act, One Big Beautiful Bill Act